MELINDA: Mobile-based Lifestyle Intervention in Women With Glucose Intolerance After Gestational Diabetes
Study Details
Study Description
Brief Summary
Although lifestyle modification programs have been shown to be effective in preventing diabetes in older populations, interventions in women with recent gestational diabetes (GDM) clearly need to be adapted to address their unique barriers to behavior change in order to optimize adherence. The low participating rates in many studies using individual or group sessions, reflect how difficult it is to engage women in the first years postpartum. Since women with glucose intolerance (prediabetes) have the highest risk to develop type 2 diabetes (T2DM), we designed the MELINDA pilot study, a randomized controlled trial with 1 year of follow-up to evaluate the efficacy and feasibility of a telephone -and mobile (app) based lifestyle coaching intervention in women with glucose intolerance after a recent history of GDM to promote a healthy lifestyle.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| No Intervention: control group Women in the control group will receive follow-up as in normal routine with referral to primary care. They will receive an OGTT after 1 year as part of the trial. |
|
| Other: intervention group A mobile-based lifestyle intervention |
Behavioral: mobile-based lifestyle intervention
one face-to-face coaching within 2 weeks after randomization, monthly telephonic coaching -and continuous use of the app as needed
|
Outcome Measures
Primary Outcome Measures
- weight-loss goal [1 year]
reaching the weight-loss goal ≥5% of body weight when overweight or obese or returning to pre-gravid weight if normal BMI
Secondary Outcome Measures
- diabetes [1 year]
development of type 2 diabetes based on the ADA criteria
- prediabetes [6-16 weeks postpartum]
prevalence of prediabetes based on the ADA criteria
- prediabetes [1 year postpartum]
prevalence of prediabetes based on the ADA criteria
- metabolic syndrome [1 year]
development of a metabolic syndrome based on the WHO criteria
- metabolic syndrome [6-16 weeks postpartum]
development of a metabolic syndrome based on the WHO criteria
- insulin resistance Matsuda [1 year]
insulin resistance measured by Matsuda index
- insulin resistance HOMA-IR [1 year]
insulin resistance measured by HOMA-IR
- beta-cell function ISSI-2 index [1 year]
beta-cell function measured by ISSI-2 index
- beta-cell function insulinogenic index [1 year]
beta-cell function measured by insulinogenic index
- beta-cell function HOMA-B [1 year]
beta-cell function measured by HOMA-B
- weight loss [1 year]
mean weight loss
- duration breastfeeding [1 year]
self-designed questionnaire to evaluate duration of breastfeeding
- rate exclusive breastfeeding [1 year]
self-designed questionnaire to evaluate rate of exclusive breastfeeding
- quality of life [1 year]
SF-36 questionnaire
- depression [1 year]
CES-D questionnaire
- anxiety [1 year]
STAI-6 questionnaire
- motivation for behavior change [1 year]
the TSRQ
- dietary quality [1 year]
Flemish FFQ
- physical activity IPAQ [1 year]
IPAQ questionnaire
- physical activity pedometer [1 year]
pedometer
- diabetes risk perception [1 year]
diabetes risk perception questionnaire
- Sence of Coherence [1 year]
Sence of Coherence (SOC) questionnaire
Eligibility Criteria
Criteria
Inclusion Criteria:
-
aged 18 or older
-
GDM based on the 2013 WHO criteria
-
glucose intolerance (prediabetes based on the ADA criteria) based on the 75g OGTT 6-16 weeks after delivery
Exclusion Criteria:
-
diabetes;
-
current use of metformin;
-
normal glucose tolerance (ADA criteria);
-
health limitations or treatments which would restrict the participation in the intervention trial.
-
Has no smartphone
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | OLV Aalst-Asse | Aalst | Oost-Vlaanderen | Belgium | 9300 |
| 2 | GZA | Antwerpen | Belgium | 2018 | |
| 3 | UZA | Antwerpen | Belgium | 2560 | |
| 4 | Imelda Bonheiden | Bonheiden | Belgium | 2820 | |
| 5 | AZ Klina | Brasschaat | Belgium | 2930 | |
| 6 | AZ Groeninge Kortrijk | Kortrijk | Belgium | 8510 | |
| 7 | UZ Leuven | Leuven | Belgium | 3000 |
Sponsors and Collaborators
- Universitaire Ziekenhuizen Leuven
Investigators
- Principal Investigator: Katrien Benhalima, MD PhD, UZ Leuven
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- the Melinda study